<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36482247</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>11</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Integrative transcriptomic analysis of the amyotrophic lateral sclerosis spinal cord implicates glial activation and suggests new risk genes.</ArticleTitle><Pagination><StartPage>150</StartPage><EndPage>162</EndPage><MedlinePgn>150-162</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41593-022-01205-3</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a progressively fatal neurodegenerative disease affecting motor neurons in the brain and spinal cord. In this study, we investigated gene expression changes in ALS via RNA sequencing in 380 postmortem samples from cervical, thoracic and lumbar spinal cord segments from 154 individuals with ALS and 49 control individuals. We observed an increase in microglia and astrocyte gene expression, accompanied by a decrease in oligodendrocyte gene expression. By creating a gene co-expression network in the ALS samples, we identified several activated microglia modules that negatively correlate with retrospective disease duration. We mapped molecular quantitative trait loci and found several potential ALS risk loci that may act through gene expression or splicing in the spinal cord and assign putative cell types for FNBP1, ACSL5, SH3RF1 and NFASC. Finally, we outline how common genetic variants associated with splicing of C9orf72 act as proxies for the well-known repeat expansion, and we use the same mechanism to suggest ATXN3 as a putative risk gene.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s), under exclusive licence to Springer Nature America, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Humphrey</LastName><ForeName>Jack</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-6274-6620</Identifier><AffiliationInfo><Affiliation>Nash Family Department of Neuroscience &amp; Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. jack.humphrey@mssm.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ronald M. Loeb Center for Alzheimer's Disease, Icahn School of Medicine at Mount Sinai, New York, NY, USA. jack.humphrey@mssm.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences &amp; Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. jack.humphrey@mssm.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Estelle and Daniel Maggin Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. jack.humphrey@mssm.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Venkatesh</LastName><ForeName>Sanan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Nash Family Department of Neuroscience &amp; Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences &amp; Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Pamela Sklar Division of Psychiatric Genomics, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hasan</LastName><ForeName>Rahat</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Nash Family Department of Neuroscience &amp; Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ronald M. Loeb Center for Alzheimer's Disease, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences &amp; Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Estelle and Daniel Maggin Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herb</LastName><ForeName>Jake T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Paiva Lopes</LastName><ForeName>Katia</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-0240-0126</Identifier><AffiliationInfo><Affiliation>Nash Family Department of Neuroscience &amp; Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ronald M. Loeb Center for Alzheimer's Disease, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences &amp; Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Estelle and Daniel Maggin Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>K&#xfc;&#xe7;&#xfc;kali</LastName><ForeName>Fahri</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-3835-9639</Identifier><AffiliationInfo><Affiliation>Complex Genetics of Alzheimer's Disease Group, Center for Molecular Neurology, VIB, Antwerp, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Byrska-Bishop</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>New York Genome Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Evani</LastName><ForeName>Uday S</ForeName><Initials>US</Initials><AffiliationInfo><Affiliation>New York Genome Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Narzisi</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-1118-8849</Identifier><AffiliationInfo><Affiliation>New York Genome Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fagegaltier</LastName><ForeName>Delphine</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>New York Genome Center, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Genomics of Neurodegenerative Disease, New York Genome Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>NYGC ALS Consortium</CollectiveName></Author><Author ValidYN="Y"><LastName>Sleegers</LastName><ForeName>Kristel</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-0283-2332</Identifier><AffiliationInfo><Affiliation>Complex Genetics of Alzheimer's Disease Group, Center for Molecular Neurology, VIB, Antwerp, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Phatnani</LastName><ForeName>Hemali</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>New York Genome Center, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Genomics of Neurodegenerative Disease, New York Genome Center, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Columbia University Irving Medical Center, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knowles</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>New York Genome Center, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Computer Science, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fratta</LastName><ForeName>Pietro</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-8762-8188</Identifier><AffiliationInfo><Affiliation>Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raj</LastName><ForeName>Towfique</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-9355-5704</Identifier><AffiliationInfo><Affiliation>Nash Family Department of Neuroscience &amp; Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. towfique.raj@mssm.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ronald M. Loeb Center for Alzheimer's Disease, Icahn School of Medicine at Mount Sinai, New York, NY, USA. towfique.raj@mssm.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences &amp; Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. towfique.raj@mssm.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Estelle and Daniel Maggin Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. towfique.raj@mssm.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/S006508/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>NIA R56-AG055824</GrantID><Agency>Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.)</Agency><Country/></Grant><Grant><GrantID>S10 OD026880</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T3GM007280</GrantID><Agency>Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.)</Agency><Country/></Grant><Grant><GrantID>U54 NS123743</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/W005190/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>S10 OD018522</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/M008606/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>NIA U01-AG068880</GrantID><Agency>Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2023 Feb;19(2):67</RefSource><PMID Version="1">36596934</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059467" MajorTopicYN="N">Transcriptome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>8</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>9</Day><Hour>0</Hour><Minute>54</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36482247</ArticleId><ArticleId IdType="doi">10.1038/s41593-022-01205-3</ArticleId><ArticleId IdType="pii">10.1038/s41593-022-01205-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ravits, J. M. &amp; La Spada, A. R. ALS motor phenotype heterogeneity, focality, and spread: deconstructing motor neuron degeneration. Neurology 73, 805&#x2013;811 (2009).</Citation></Reference><Reference><Citation>Byrne, S. et al. Rate of familial amyotrophic lateral sclerosis: a systematic review and meta-analysis. J. Neurol. Neurosurg. Psychiatry 82, 623&#x2013;627 (2011).</Citation></Reference><Reference><Citation>Majounie, E. et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol. 11, 323&#x2013;330 (2012).</Citation></Reference><Reference><Citation>Renton, A. E., Chi&#xf2;, A. &amp; Traynor, B. J. State of play in amyotrophic lateral sclerosis genetics. Nat. Neurosci. 17, 17&#x2013;23 (2014).</Citation></Reference><Reference><Citation>Cirulli, E. T. et al. Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. Nat. Methods 347, 1436&#x2013;1441 (2016).</Citation></Reference><Reference><Citation>Kenna, K. P. et al. NEK1 variants confer susceptibility to amyotrophic lateral sclerosis. Nat. Genet. 48, 1037&#x2013;1042 (2016).</Citation></Reference><Reference><Citation>Nicolas, A. et al. Genome-wide analyses identify KIF5A as a novel ALS gene. Neuron 97, 1268&#x2013;1283 (2018).</Citation></Reference><Reference><Citation>van Es, M. A. et al. Genome-wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. Nat. Genet. 41, 1083&#x2013;1087 (2009).</Citation></Reference><Reference><Citation>Van Rheenen, W. et al. Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nat. Genet. 48, 1043&#x2013;1048 (2016).</Citation></Reference><Reference><Citation>van Rheenen, W. et al. Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. Nat. Genet. 53, 1636&#x2013;1648 (2021).</Citation></Reference><Reference><Citation>Elden, A. C. et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature 466, 1069&#x2013;1075 (2010).</Citation></Reference><Reference><Citation>Tazelaar, G. H. P. et al. ATXN1 repeat expansions confer risk for amyotrophic lateral sclerosis and contribute to TDP-43 mislocalization. Brain Commun. 2, fcaa064 (2020).</Citation></Reference><Reference><Citation>Lattante, S. et al. ATXN1 intermediate-length polyglutamine expansions are associated with amyotrophic lateral sclerosis. Neurobiol. Aging 64, 157.e1&#x2013;157.e5 (2018).</Citation></Reference><Reference><Citation>Hirano, M. et al. Noncoding repeat expansions for ALS in Japan are associated with the ATXN8OS gene. Neurol. Genet. 4, e252 (2018).</Citation></Reference><Reference><Citation>Giambartolomei, C. et al. Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. PLoS Genet. 10, e1004383 (2014).</Citation></Reference><Reference><Citation>Young, A. M. H. et al. A map of transcriptional heterogeneity and regulatory variation in human microglia. Nat. Genet. 53, 861&#x2013;868 (2021).</Citation></Reference><Reference><Citation>Novikova, G. et al. Integration of Alzheimer&#x2019;s disease genetics and myeloid genomics identifies disease risk regulatory elements and genes. Nat. Commun. 12, 1610 (2021).</Citation></Reference><Reference><Citation>Lopes, K. et al. Genetic analysis of the human microglial transcriptome across brain regions, aging and disease pathologies. Nat. Genet. 54, 4&#x2013;17 (2022).</Citation></Reference><Reference><Citation>Pramatarova, A., Lagani&#xe8;re, J., Roussel, J., Brisebois, K. &amp; Rouleau, G. A. Neuron-specific expression of mutant superoxide dismutase 1 in transgenic mice does not lead to motor impairment. J. Neurosci. 21, 3369&#x2013;3374 (2001).</Citation></Reference><Reference><Citation>Jaarsma, D., Teuling, E., Haasdijk, E. D., De Zeeuw, C. I. &amp; Hoogenraad, C. C. Neuron-specific expression of mutant superoxide dismutase is sufficient to induce amyotrophic lateral sclerosis in transgenic mice. J. Neurosci. 28, 2075&#x2013;2088 (2008).</Citation></Reference><Reference><Citation>Yamanaka, K. et al. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat. Neurosci. 11, 251&#x2013;253 (2008).</Citation></Reference><Reference><Citation>Lepore, A. C. et al. Focal transplantation-based astrocyte replacement is neuroprotective in a model of motor neuron disease. Nat. Neurosci. 11, 1294&#x2013;1301 (2008).</Citation></Reference><Reference><Citation>Boill&#xe9;e, S. et al. Onset and progression in inherited ALS determined by motor neurons and microglia. Science 312, 1389&#x2013;1392 (2006).</Citation></Reference><Reference><Citation>Wang, L., Sharma, K., Grisotti, G. &amp; Roos, R. P. The effect of mutant SOD1 dismutase activity on non-cell autonomous degeneration in familial amyotrophic lateral sclerosis. Neurobiol. Dis. 35, 234&#x2013;240 (2009).</Citation></Reference><Reference><Citation>Phatnani, H. P. et al. Intricate interplay between astrocytes and motor neurons in ALS. Proc. Natl Acad. Sci. USA 110, E756&#x2013;E765 (2013).</Citation></Reference><Reference><Citation>Town, T., Nikolic, V. &amp; Tan, J. The microglial &#x2018;activation&#x2019; continuum: from innate to adaptive responses. J. Neuroinflammation 2, 24 (2005).</Citation></Reference><Reference><Citation>Chiu, I. M. et al. A neurodegeneration-specific gene-expression signature of acutely isolated microglia from an amyotrophic lateral sclerosis mouse model. Cell Rep. 4, 385&#x2013;401 (2013).</Citation></Reference><Reference><Citation>Liddelow, S. A. et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541, 481&#x2013;487 (2017).</Citation></Reference><Reference><Citation>Zhao, W. et al. Activated microglia initiate motor neuron injury by a nitric oxide and glutamate-mediated mechanism. J. Neuropathol. Exp. Neurol. 63, 964&#x2013;977 (2004).</Citation></Reference><Reference><Citation>Haidet-Phillips, A. M. et al. Astrocytes from familial and sporadic ALS patients are toxic to motor neurons. Nat. Biotechnol. 29, 824&#x2013;828 (2011).</Citation></Reference><Reference><Citation>Guttenplan, K. A. et al. Knockout of reactive astrocyte activating factors slows disease progression in an ALS mouse model. Nat. Commun. 11, 3753 (2020).</Citation></Reference><Reference><Citation>D&#x2019;Erchia, A. M. et al. Massive transcriptome sequencing of human spinal cord tissues provides new insights into motor neuron degeneration in ALS. Sci. Rep. 7, 10046 (2017).</Citation></Reference><Reference><Citation>Brohawn, D. G., O&#x2019;Brien, L. C. &amp; Bennett, J. P. Jr. RNAseq analyses identify tumor necrosis factor-mediated inflammation as a major abnormality in ALS spinal cord. PLoS ONE 11, e0160520 (2016).</Citation></Reference><Reference><Citation>Andr&#xe9;s-Benito, P., Moreno, J., Aso, E., Povedano, M. &amp; Ferrer, I. Amyotrophic lateral sclerosis, gene deregulation in the anterior horn of the spinal cord and frontal cortex area 8: implications in frontotemporal lobar degeneration. Aging 9, 823&#x2013;851 (2017).</Citation></Reference><Reference><Citation>Dols-Icardo, O. et al. Motor cortex transcriptome reveals microglial key events in amyotrophic lateral sclerosis. Neurol. Neuroimmunol. Neuroinflamm. 7, e829 (2020).</Citation></Reference><Reference><Citation>Thompson, A. G. et al. Cerebrospinal fluid macrophage biomarkers in amyotrophic lateral sclerosis. Ann. Neurol. 83, 258&#x2013;268 (2018).</Citation></Reference><Reference><Citation>Tanaka, H. et al. The potential of GPNMB as novel neuroprotective factor in amyotrophic lateral sclerosis. Sci. Rep. 2, 573 (2012).</Citation></Reference><Reference><Citation>Oeckl, P. et al. Proteomics in cerebrospinal fluid and spinal cord suggests UCHL1, MAP2 and GPNMB as biomarkers and underpins importance of transcriptional pathways in amyotrophic lateral sclerosis. Acta Neuropathol. 139, 119&#x2013;134 (2020).</Citation></Reference><Reference><Citation>H&#xfc;ttenrauch, M. et al. Glycoprotein NMB: a novel Alzheimer&#x2019;s disease associated marker expressed in a subset of activated microglia. Acta Neuropathol. Commun. 6, 108 (2018).</Citation></Reference><Reference><Citation>Murthy, M. N. et al. Increased brain expression of GPNMB is associated with genome wide significant risk for Parkinson&#x2019;s disease on chromosome 7p15.3. Neurogenetics 18, 121&#x2013;133 (2017).</Citation></Reference><Reference><Citation>Nalls, M. A. et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson&#x2019;s disease: a meta-analysis of genome-wide association studies. Lancet Neurol. 18, 1091&#x2013;1102 (2019).</Citation></Reference><Reference><Citation>Halter, B. et al. Oxidative stress in skeletal muscle stimulates early expression of Rad in a mouse model of amyotrophic lateral sclerosis. Free Radic. Biol. Med. 48, 915&#x2013;923 (2010).</Citation></Reference><Reference><Citation>Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545&#x2013;15550 (2005).</Citation></Reference><Reference><Citation>Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417&#x2013;425 (2015).</Citation></Reference><Reference><Citation>Mathys, H. et al. Single-cell transcriptomic analysis of Alzheimer&#x2019;s disease. Nature 570, 332&#x2013;337 (2019).</Citation></Reference><Reference><Citation>Keren-Shaul, H. et al. A unique microglia type associated with restricting development of Alzheimer&#x2019;s disease. Cell 169, 1276&#x2013;1290 (2017).</Citation></Reference><Reference><Citation>Habib, N. et al. Disease-associated astrocytes in Alzheimer&#x2019;s disease and aging. Nat. Neurosci. 23, 701&#x2013;706 (2020).</Citation></Reference><Reference><Citation>Zamanian, J. L. et al. Genomic analysis of reactive astrogliosis. J. Neurosci. 32, 6391&#x2013;6410 (2012).</Citation></Reference><Reference><Citation>Chen, W.-T. et al. Spatial transcriptomics and in situ sequencing to study Alzheimer&#x2019;s disease. Cell 182, 976&#x2013;991 (2020).</Citation></Reference><Reference><Citation>Darmanis, S. et al. A survey of human brain transcriptome diversity at the single cell level. Proc. Natl Acad. Sci. USA 112, 7285&#x2013;7290 (2015).</Citation></Reference><Reference><Citation>Wang, X., Park, J., Susztak, K., Zhang, N. R. &amp; Li, M. Bulk tissue cell type deconvolution with multi-subject single-cell expression reference. Nat. Commun. 10, 380 (2019).</Citation></Reference><Reference><Citation>Hunt, G. J., Freytag, S., Bahlo, M. &amp; Gagnon-Bartsch, J. A. dtangle: accurate and robust cell type deconvolution. Bioinformatics 35, 2093&#x2013;2099 (2019).</Citation></Reference><Reference><Citation>Skene, N. G. &amp; Grant, S. G. N. Identification of vulnerable cell types in major brain disorders using single cell transcriptomes and expression weighted cell type enrichment. Front. Neurosci. 10, 16 (2016).</Citation></Reference><Reference><Citation>Prudencio, M. et al. Distinct brain transcriptome profiles in C9orf72-associated and sporadic ALS. Nat. Neurosci. 18, 1175&#x2013;1182 (2015).</Citation></Reference><Reference><Citation>Dickson, D. W. et al. Extensive transcriptomic study emphasizes importance of vesicular transport in C9orf72 expansion carriers. Acta Neuropathol. Commun. 7, 150 (2019).</Citation></Reference><Reference><Citation>Dolzhenko, E. et al. ExpansionHunter: a sequence-graph based tool to analyze variation in short tandem repeat regions. Preprint at https://www.biorxiv.org/content/10.1101/572545v2 (2019).</Citation></Reference><Reference><Citation>Jackson, J. L. et al. Elevated methylation levels, reduced expression levels, and frequent contractions in a clinical cohort of C9orf72 expansion carriers. Mol. Neurodegener. 15, 7 (2020).</Citation></Reference><Reference><Citation>Oldham, M. C. et al. Functional organization of the transcriptome in human brain. Nat. Neurosci. 11, 1271&#x2013;1282 (2008).</Citation></Reference><Reference><Citation>Prudencio, M. et al. Truncated stathmin-2 is a marker of TDP-43 pathology in frontotemporal dementia. J. Clin. Invest. 130, 6080&#x2013;6092 (2020).</Citation></Reference><Reference><Citation>Klim, J. R. et al. ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair. Nat. Neurosci. 22, 167&#x2013;179 (2019).</Citation></Reference><Reference><Citation>Melamed, Z. et al. Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration. Nat. Neurosci. 22, 180&#x2013;190 (2019).</Citation></Reference><Reference><Citation>Ticozzi, N. et al. Paraoxonase gene mutations in amyotrophic lateral sclerosis. Ann. Neurol. 68, 102&#x2013;107 (2010).</Citation></Reference><Reference><Citation>Li, Y. I. et al. Annotation-free quantification of RNA splicing using LeafCutter. Nat. Genet. 50, 151&#x2013;158 (2018).</Citation></Reference><Reference><Citation>de Paiva Lopes, K. et al. Genetic analysis of the human microglial transcriptome across brain regions, aging and disease pathologies. Nat. Genet. 54, 4&#x2013;17 (2022).</Citation></Reference><Reference><Citation>GTEx Consortium. The GTEx Consortium atlas of genetic regulatory effects across human tissues. Science 369, 1318&#x2013;1330 (2020).</Citation></Reference><Reference><Citation>Kim-Hellmuth, S. et al. Cell type-specific genetic regulation of gene expression across human tissues. Science 369, eaaz8528 (2020).</Citation></Reference><Reference><Citation>Li, Y. I., Wong, G., Humphrey, J. &amp; Raj, T. Prioritizing Parkinson&#x2019;s disease genes using population-scale transcriptomic data. Nat. Commun. 10, 994 (2019).</Citation></Reference><Reference><Citation>Kelley, K. W., Nakao-Inoue, H., Molofsky, A. V. &amp; Oldham, M. C. Variation among intact tissue samples reveals the core transcriptional features of human CNS cell classes. Nat. Neurosci. 21, 1171&#x2013;1184 (2018).</Citation></Reference><Reference><Citation>O&#x2019;Rourke, J. G. et al. C9orf72 is required for proper macrophage and microglial function in mice. Science 351, 1324&#x2013;1329 (2016).</Citation></Reference><Reference><Citation>Renton, A. E. et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72, 257&#x2013;268 (2011).</Citation></Reference><Reference><Citation>DeJesus-Hernandez, M. et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72, 245&#x2013;256 (2011).</Citation></Reference><Reference><Citation>Nakamura, R. et al. A multi-ethnic meta-analysis identifies novel genes, including ACSL5, associated with amyotrophic lateral sclerosis. Commun. Biol. 3, 526 (2020).</Citation></Reference><Reference><Citation>Paulson, H. Machado&#x2013;Joseph Disease/Spinocerebellar Ataxia Type 3. in Genetic Instabilities and Neurological Diseases 2nd ed 363&#x2013;377 (Academic Press, 2006).</Citation></Reference><Reference><Citation>Seidel, K. et al. Axonal inclusions in spinocerebellar ataxia type 3. Acta Neuropathol. 120, 449&#x2013;460 (2010).</Citation></Reference><Reference><Citation>Prudencio, M. et al. Toward allele-specific targeting therapy and pharmacodynamic marker for spinocerebellar ataxia type 3. Sci. Transl. Med. 12, eabb7086 (2020).</Citation></Reference><Reference><Citation>Kang, S. H. et al. Degeneration and impaired regeneration of gray matter oligodendrocytes in amyotrophic lateral sclerosis. Nat. Neurosci. 16, 571&#x2013;579 (2013).</Citation></Reference><Reference><Citation>Zondler, L. et al. Peripheral monocytes are functionally altered and invade the CNS in ALS patients. Acta Neuropathol. 132, 391&#x2013;411 (2016).</Citation></Reference><Reference><Citation>Saul, J. et al. Global alterations to the choroid plexus blood&#x2013;CSF barrier in amyotrophic lateral sclerosis. Acta Neuropathol. Commun. 8, 92 (2020).</Citation></Reference><Reference><Citation>M&#xe5;nberg, A. et al. Publisher correction: Altered perivascular fibroblast activity precedes ALS disease onset. Nat. Med. 27, 1308 (2021).</Citation></Reference><Reference><Citation>Brettschneider, J. et al. Microglial activation correlates with disease progression and upper motor neuron clinical symptoms in amyotrophic lateral sclerosis. PLoS ONE 7, e39216 (2012).</Citation></Reference><Reference><Citation>Varghese, A. M. et al. Chitotriosidase, a biomarker of amyotrophic lateral sclerosis, accentuates neurodegeneration in spinal motor neurons through neuroinflammation. J. Neuroinflammation 17, 232 (2020).</Citation></Reference><Reference><Citation>Pagliardini, V. et al. Chitotriosidase and lysosomal enzymes as potential biomarkers of disease progression in amyotrophic lateral sclerosis: a survey clinic-based study. J. Neurol. Sci. 348, 245&#x2013;250 (2015).</Citation></Reference><Reference><Citation>Wainberg, M. et al. Opportunities and challenges for transcriptome-wide association studies. Nat. Genet. 51, 592&#x2013;599 (2019).</Citation></Reference><Reference><Citation>Tam, O. H. et al. Postmortem cortex samples identify distinct molecular subtypes of ALS: retrotransposon activation, oxidative stress, and activated glia. Cell Rep. 29, 1164&#x2013;1177 (2019).</Citation></Reference><Reference><Citation>Schroeder, A. et al. The RIN: an RNA integrity number for assigning integrity values to RNA measurements. BMC Mol. Biol. 7, 3 (2006).</Citation></Reference><Reference><Citation>Di Tommaso, P. et al. Nextflow enables reproducible computational workflows. Nat. Biotechnol. 35, 316&#x2013;319 (2017).</Citation></Reference><Reference><Citation>Bolduc, B. Quality control of reads using Trimmomatic (Cyverse) V.1. https://doi.org/10.17504/protocols.io.ewbbfan (2016).</Citation></Reference><Reference><Citation>Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15&#x2013;21 (2013).</Citation></Reference><Reference><Citation>Harrow, J., Frankish, A., Gonzalez, J. M. &amp; Frazer, K. A. GENCODE: the reference human genome annotation for the ENCODE Project. Genome Res. 22, 1760&#x2013;1774 (2012).</Citation></Reference><Reference><Citation>Li, B. &amp; Dewey, C. N. RSEM: accurate transcript quantification from RNA-seq data with or without a reference genome. BMC Bioinformatics 12, 323 (2011).</Citation></Reference><Reference><Citation>Li, H. et al. The sequence alignment/Map format and SAMtools. Bioinformatics 25, 2078&#x2013;2079 (2009).</Citation></Reference><Reference><Citation>Ewels, P., Magnusson, M., Lundin, S. &amp; K&#xe4;ller, M. MultiQC: summarize analysis results for multiple tools and samples in a single report. Bioinformatics 32, 3047&#x2013;3048 (2016).</Citation></Reference><Reference><Citation>Hoffman, G. E. &amp; Schadt, E. E. variancePartition: interpreting drivers of variation in complex gene expression studies. BMC Bioinformatics 17, 483 (2016).</Citation></Reference><Reference><Citation>Price, A. L. et al. Principal components analysis corrects for stratification in genome-wide association studies. Nat. Genet. 38, 904&#x2013;909 (2006).</Citation></Reference><Reference><Citation>Law, C. W., Chen, Y., Shi, W. &amp; Smyth, G. K. voom: precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol. 15, R29 (2014).</Citation></Reference><Reference><Citation>Risso, D., Schwartz, K., Sherlock, G. &amp; Dudoit, S. GC-content normalization for RNA-seq data. BMC Bioinformatics 12, 480 (2011).</Citation></Reference><Reference><Citation>Yu, G., Wang, L.-G., Han, Y. &amp; He, Q.-Y. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 16, 284&#x2013;287 (2012)</Citation></Reference><Reference><Citation>Franz&#xe9;n, O., Gan, L.-M. &amp; Bj&#xf6;rkegren, J. L. M. PanglaoDB: a web server for exploration of mouse and human single-cell RNA sequencing data. Database (Oxford) 2019, baz046 (2019).</Citation></Reference><Reference><Citation>Mancarci, B. O. et al. Cross-laboratory analysis of brain cell type transcriptomes with applications to interpretation of bulk tissue data. eNeuro 4, ENEURO.0212-17.2017 (2017).</Citation></Reference><Reference><Citation>Mancarci, O. &amp; French, L. Package &#x2018;homologene&#x2bc;: quick access to homologene and gene annotation updates. https://cran.r-project.org/web/packages/homologene/homologene.pdf (2019).</Citation></Reference><Reference><Citation>Reimand, J., Kull, M., Peterson, H., Hansen, J. &amp; Vilo, J. g:Profiler&#x2014;a web-based toolset for functional profiling of gene lists from large-scale experiments. Nucleic Acids Res. 35, W193&#x2013;W200 (2007).</Citation></Reference><Reference><Citation>Love, M. I., Soneson, C. &amp; Robinson, M. D. Importing transcript abundance datasets with tximport. https://bioconductor.statistik.tu-dortmund.de/packages/3.6/bioc/vignettes/tximport/inst/doc/tximport.html (2017).</Citation></Reference><Reference><Citation>Stegle, O., Parts, L., Piipari, M., Winn, J. &amp; Durbin, R. Using probabilistic estimation of expression residuals (PEER) to obtain increased power and interpretability of gene expression analyses. Nat. Protoc. 7, 500 (2012).</Citation></Reference><Reference><Citation>Taylor-Weiner, A. et al. Scaling computational genomics to millions of individuals with GPUs. Genome Biol. 20, 228 (2019).</Citation></Reference><Reference><Citation>Feng, Y.-Y. et al. RegTools: integrated analysis of genomic and transcriptomic data for discovery of splicing variants in cancer. Preprint at https://www.biorxiv.org/content/10.1101/436634v5 (2018).</Citation></Reference><Reference><Citation>Storey, J. D. The positive false discovery rate: a Bayesian interpretation and the q-value. Ann. Stat. 31, 2013&#x2013;2035 (2003).</Citation></Reference><Reference><Citation>Oscanoa, J. et al. SNPnexus: a web server for functional annotation of human genome sequence variation (2020 update). Nucleic Acids Res. 48, W185&#x2013;W192 (2020).</Citation></Reference><Reference><Citation>Myers, T. A., Chanock, S. J. &amp; Machiela, M. J. LDlinkR: an R package for rapidly calculating linkage disequilibrium statistics in diverse populations. Front. Genet. 11, 157 (2020).</Citation></Reference><Reference><Citation>Wickham, H. ggplot2: Elegant Graphics for Data Analysis (Springer-Verlag, 2009).</Citation></Reference><Reference><Citation>Slowikowski, K. ggrepel: repulsive text and label geoms for &#x2018;ggplot2. https://cran.microsoft.com/snapshot/2016-08-05/web/packages/ggrepel/index.html (2016).</Citation></Reference><Reference><Citation>Tang, Y., Horikoshi, M. &amp; Li, W. ggfortify: unified interface to visualize statistical results of popular R packages. The R Journal 8, 474&#x2013;485 (2016).</Citation></Reference><Reference><Citation>Pedersen, T. L. patchwork: the composer of plots. https://mran.revolutionanalytics.com/snapshot/2020-04-25/web/packages/patchwork/index.html (2019).</Citation></Reference><Reference><Citation>Xu, S. et al. Use ggbreak to effectively utilize plotting space to deal with large datasets and outliers. Front. Genet. 12, 774846 (2021).</Citation></Reference><Reference><Citation>Yin, T., Cook, D. &amp; Lawrence, M. ggbio: an R package for extending the grammar of graphics for genomic data. Genome Biol. 13, R77 (2012).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>